SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : The Thread Formerly Known as No Rest For The Wicked
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Corwin_of_Amber who wrote (86908)1/18/2000 9:13:00 PM
From: out_of_the_loop  Read Replies (1) of 90042
 
VPHM is a decent company and pleconaril is probably going to be a decent drug. It will not cure the common cold. That is hype. It cuts symptoms from 10-14 days to about 8-9 days. Pleconaril will have some uses but not for the common cold.

I am invested in GUMM so I am looking at this partially as a GUMM investor who is prejudiced in favor of Zicam. Zicam costs less than $10 in most places, has enough doses for at least 2 colds, cuts the duration to about 2 days, and is over the counter (does not require prescription). Studies have been done regarding its effectiveness as prophylaxis (preventive) versus colds. The company is being very secretive about the results because their inital studies were accepted by a journal and then withdrawn by the journal following a breech of publicity. If the results were bad, it would be material information that they would have to provide for investors.

The only caveat is that Zicam only works against rhinovirus infections specifically and not all colds are caused by rhinovirus infections.

In any case, pleconaril from VPHM will never be a first line cold medication in my opinion. It cost $50-$100 per cold and requires a prescription. Most people would rather go to a store and buy what works now. Pleconaril has not yet received FDA approval and the next tests do not start until September. The publicity over the weekend was hype and somewhat irresponsible since it is not only not a cure for the common cold, it hardly cuts the symptom duration - only by 20-30%.

Do your own dd.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News